[go: up one dir, main page]

MX2016010835A - Terapeuticos dirigidos a la glucosa. - Google Patents

Terapeuticos dirigidos a la glucosa.

Info

Publication number
MX2016010835A
MX2016010835A MX2016010835A MX2016010835A MX2016010835A MX 2016010835 A MX2016010835 A MX 2016010835A MX 2016010835 A MX2016010835 A MX 2016010835A MX 2016010835 A MX2016010835 A MX 2016010835A MX 2016010835 A MX2016010835 A MX 2016010835A
Authority
MX
Mexico
Prior art keywords
therapeutics
glycotargeting
glycotargeting therapeutics
useful
treatment
Prior art date
Application number
MX2016010835A
Other languages
English (en)
Other versions
MX388754B (es
Inventor
A Hubbell Jeffrey
Kontos Stephane
Kristen LORENTZ Marie
David Wilson Scott
Gai Shuning
Original Assignee
Anokion Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anokion Sa filed Critical Anokion Sa
Publication of MX2016010835A publication Critical patent/MX2016010835A/es
Publication of MX388754B publication Critical patent/MX388754B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Terapéuticos dirigidos a la glucosa que son útiles en el tratamiento de un rechazo de trasplante, enfermedades autoinmunes, alergia a los alimentos, y respuesta inmune contra un agente terapéutico.
MX2016010835A 2014-02-21 2015-02-20 Terapéuticos dirigidos a la glucosa. MX388754B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942942P 2014-02-21 2014-02-21
PCT/IB2015/001145 WO2015140648A2 (en) 2014-02-21 2015-02-20 Glycotargeting therapeutics

Publications (2)

Publication Number Publication Date
MX2016010835A true MX2016010835A (es) 2017-07-11
MX388754B MX388754B (es) 2025-03-20

Family

ID=53762221

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010835A MX388754B (es) 2014-02-21 2015-02-20 Terapéuticos dirigidos a la glucosa.
MX2021012636A MX2021012636A (es) 2014-02-21 2016-08-19 Terapeuticos dirigidos a la glucosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012636A MX2021012636A (es) 2014-02-21 2016-08-19 Terapeuticos dirigidos a la glucosa.

Country Status (16)

Country Link
US (4) US10821157B2 (es)
EP (2) EP3909603A1 (es)
JP (4) JP6744227B2 (es)
KR (3) KR20240154672A (es)
CN (1) CN106456743A (es)
AU (3) AU2015233084B2 (es)
CA (1) CA2946064C (es)
DK (1) DK3107563T3 (es)
EA (1) EA201691686A1 (es)
ES (1) ES2874884T3 (es)
IL (2) IL247283B (es)
LT (1) LT3107563T (es)
MX (2) MX388754B (es)
NZ (1) NZ723879A (es)
SG (2) SG10202010936RA (es)
WO (1) WO2015140648A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN108348581B (zh) 2015-09-04 2022-07-01 斯克利普斯研究所 胰岛素免疫球蛋白融合蛋白
CN108430497B (zh) * 2015-09-19 2024-05-07 洛桑聚合联合学院 糖靶向治疗剂
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) * 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN114728056A (zh) * 2019-09-20 2022-07-08 阿诺基昂股份公司 用于诱导抗原特异性免疫耐受的化合物
IL294515A (en) 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins
CN111214461B (zh) * 2020-03-24 2021-04-16 河南大学 糖靶向修饰siRNA纳米粒子的制备及应用
CA3183993A1 (en) * 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
WO2022035997A1 (en) * 2020-08-11 2022-02-17 Avilar Therapeutics, Inc. In vivo assembly of asgpr binding therapeutics
WO2022154127A1 (ja) * 2021-01-18 2022-07-21 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
US20240309084A1 (en) * 2021-01-19 2024-09-19 Novartis Ag Degradation of extracellular targets
WO2022192478A1 (en) * 2021-03-10 2022-09-15 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
JP2024517812A (ja) 2021-05-03 2024-04-23 アヴィラー セラピューティクス インコーポレイテッド 免疫グロブリン及びその他のタンパク質を分解する強力なａｓｇｐｒ結合性化合物
WO2023288033A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025210538A1 (en) * 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5742852A (en) 1980-08-27 1982-03-10 Seikagaku Kogyo Co Ltd Erythrocyte sensitized with antibody of polysaccharide of hemolytic streptococcus
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5162512A (en) 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
CA1203164A (en) 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0119650A3 (en) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
JPS59173762A (ja) 1983-03-22 1984-10-01 Green Cross Corp:The 逆受身抗体赤血球凝集反応用試薬
CA1260827A (en) 1984-08-31 1989-09-26 Richard C. Siegel Antibody-metal ion complexes
AU583854B2 (en) 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
CA1330378C (en) 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US5086002A (en) 1987-09-07 1992-02-04 Agen Biomedical, Ltd. Erythrocyte agglutination assay
US20030022826A1 (en) 1987-09-08 2003-01-30 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens or infectious agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
EP0505357B1 (en) 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
JPH0436185A (ja) 1990-03-28 1992-02-06 Kyowa Hakko Kogyo Co Ltd 融合抗原ポリペプチド
AU8869291A (en) 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
KR950014915B1 (ko) 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
WO1993018160A1 (en) 1992-03-11 1993-09-16 Kenneth Francis Prendergast Anti-viral fusion peptides
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1995006737A1 (en) 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
US5681571A (en) 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
ES2207646T3 (es) 1994-02-28 2004-06-01 The University Of Virginia Patent Foundation Heteropolimeros basados en antigenos para el tratamiento de enfermedades autoinmunitarias.
US5698679A (en) 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5718915A (en) 1994-10-31 1998-02-17 Burstein Laboratories, Inc. Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US20020187131A1 (en) 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
WO1996023882A1 (en) 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
ATE458499T1 (de) 1995-06-07 2010-03-15 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6060054A (en) 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998015263A2 (en) 1996-10-09 1998-04-16 Takeda Chemical Industries, Ltd. A method for producing a microparticle
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US20090280132A1 (en) 1997-01-07 2009-11-12 Habib Zaghouani Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
WO2000001732A2 (en) 1998-07-06 2000-01-13 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20020081298A1 (en) 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20030103967A1 (en) 1997-01-07 2003-06-05 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20070218053A1 (en) 1997-01-07 2007-09-20 Habib Zaghouani Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
PL336306A1 (en) 1997-04-18 2000-06-19 Biogen Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
CU22737A1 (es) 1997-04-28 2002-02-28 Ct Ingenieria Genetica Biotech Proteínas de fusión recombinantes basadas en adhesinas bacterianas para el desarrollo de ensayos diagnóstico
US6120770A (en) 1997-09-12 2000-09-19 University Of Notre Dame Du Lac Plasmodium proteins useful for preparing vaccine compositions
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
ES2322975T3 (es) 1998-01-15 2009-07-02 Center For Molecular Medicine And Immunology Componente direccionador biespecifico que comprende un anticuerpo contra el antigeno carcinoembrionario (cea) y la region de union a ligando de la subunidad alfa del receptor de il-13.
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
IL137388A (en) 1998-01-29 2005-05-17 Poly Med Inc Absorbable microparticles
US6562347B1 (en) 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
EP1093378A4 (en) 1998-05-21 2001-10-10 Univ Pennsylvania COMPOSITIONS AND TECHNIQUES FOR PREVENTING AND TREATING ANARCHIC FORMATION OF INTRAVASCULAR FIBRINOUS CLOTS
US7041287B2 (en) 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots
WO1999065948A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
WO2001022995A1 (en) 1999-09-30 2001-04-05 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
CA2416656A1 (en) 2000-06-05 2002-04-04 University Of Tennessee Corporation Compositions and methods for the endocytic presentation of immunosuppressive factors
CA2414272A1 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
AU2001281140A1 (en) 2000-08-07 2002-02-18 Entremed, Inc Anti-plasmodium compositions and methods of use
GB0019302D0 (en) 2000-08-08 2000-09-27 Univ Nottingham Trent Biological materials and the use thereof for the treatment of disease
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
WO2002055185A2 (en) 2000-10-19 2002-07-18 Eidgenoess Tech Hochschule Block copolymers for multifunctional self-assembled systems
US7470420B2 (en) 2000-12-05 2008-12-30 The Regents Of The University Of California Optical determination of glucose utilizing boronic acid adducts
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
CA2437814C (en) 2001-02-12 2008-05-13 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
DE60238801D1 (de) 2001-04-10 2011-02-10 Bioe Llc Zelltrennungszusammensetzungen und -verfahren
WO2002091146A2 (en) 2001-05-09 2002-11-14 Ecd Systems, Inc. Systems and methods for the prevention of unauthorized use and manipulation of digital content
GB0113798D0 (en) 2001-06-06 2001-07-25 Chiron Spa Antigens and vectors for vaccination
EP1409009A1 (en) 2001-06-15 2004-04-21 Nordic Vaccine Technology A/S Therapeutical vaccination
EP1417229B1 (en) 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
FR2829500B1 (fr) 2001-09-13 2003-12-12 Hemosystem Procede de concentration et de detection de germes pathogenes a partir de produits sanguins et/ou de leurs derives et dispositif pour le mettre en oeuvre
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
EP1440090A2 (en) 2001-10-23 2004-07-28 Centre for Translational Research in Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses
US20030211078A1 (en) 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
AU2003216184A1 (en) 2002-02-05 2003-09-02 The Regents Of The University Of California Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
CA2649821C (en) 2002-08-06 2016-09-20 Loma Linda University Polynucleotide sequences encoding .delta.bcl-2 for preventing and treating autoimmune diseases
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2004060910A2 (en) 2002-12-16 2004-07-22 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
ES2527414T3 (es) 2003-03-04 2015-01-23 Alexion Pharmaceuticals, Inc. Método para el tratamiento de una enfermedad autoinmune mediante la inducción de la presentación de antígeno mediante células presentadoras de antígeno que inducen tolerancia
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US20070059794A1 (en) 2003-04-28 2007-03-15 Sekisui Chemical Company Limited Chaperonin-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release formulation, and method of producing antibody against target protein
CA2524615A1 (en) 2003-05-12 2004-11-18 Tolerogen, Ltd. Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050100964A1 (en) 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
WO2005051174A2 (en) 2003-11-21 2005-06-09 The Trustees Of Columbia University In The City Of New York Nucleic acid aptamer-based compositions and methods
US20110064754A1 (en) 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
FR2869323B1 (fr) 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes
CN1976715B (zh) 2004-04-28 2014-07-30 英国技术集团国际有限公司 与腹部疾病有关的表位
JP2008504531A (ja) 2004-06-24 2008-02-14 ザ スクリップス リサーチ インスティテュート 切断可能なリンカーを有するアレイ
US8273357B2 (en) 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006034081A2 (en) 2004-09-17 2006-03-30 Massachusetts Institute Of Technology Polymers for analyte detection
JP5227592B2 (ja) 2005-02-07 2013-07-03 リポテック プロプライエタリー リミテッド アジュバント物質
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
US7811809B2 (en) 2005-06-15 2010-10-12 Saint Louis University Molecular biosensors for use in competition assays
SG10201508322SA (en) 2005-07-08 2015-11-27 Biogen Ma Inc Sp35 antibodies and uses thereof
FI20050814A0 (fi) 2005-08-11 2005-08-11 Procollagen Oy Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi
US20090130104A1 (en) 2005-10-05 2009-05-21 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US8440191B2 (en) 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
EP3097924B1 (en) * 2005-11-29 2020-01-08 Intrexon Actobiotics NV Induction of mucosal tolerance to gliadin
WO2007097934A2 (en) 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
AU2007222526A1 (en) 2006-03-09 2007-09-13 Aplagen Gmbh Modified molecules which promote hematopoiesis
CN101443351A (zh) 2006-03-09 2009-05-27 阿普拉根有限公司 修饰的促进血细胞生成的分子
US20090238883A1 (en) 2006-04-28 2009-09-24 Kren Betsy T Liver-specific nanocapsules and methods of using
US8318912B2 (en) 2006-06-23 2012-11-27 Augmenta Biologicals, Llc Targeted immune conjugate comprising an antibody to glycophorin A and a M2e peptide
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
EP2073827A4 (en) 2006-11-03 2012-04-25 Univ Northwestern THERAPY FOR MULTIPLE SCLEROSIS
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP6082174B2 (ja) 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
JP5543785B2 (ja) 2007-02-02 2014-07-09 ベイラー リサーチ インスティテュート ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原
TW200846363A (en) 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
WO2008151005A2 (en) 2007-05-31 2008-12-11 Transtarget, Inc. Compositions and methods for tissue repair
US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
TR201000668T1 (tr) 2007-07-31 2010-06-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
EP3424525A1 (en) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis
CN103768580A (zh) 2007-12-19 2014-05-07 托勒兰泽亚股份公司 治疗自身免疫和过敏性疾病的组合物及方法
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
WO2009086552A1 (en) 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
US20100316620A1 (en) 2008-02-13 2010-12-16 Vanessa Bourgeaux Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
AU2009227935B2 (en) 2008-03-28 2015-07-09 Mdna Life Sciences Inc. Aberrant mitochondrial DNA, associated fusion transcripts and hybridization probes therefor
WO2009120893A2 (en) * 2008-03-28 2009-10-01 The Regents Of The University Of California Polypeptide-polymer conjugates and methods of use thereof
US8852640B2 (en) 2008-07-03 2014-10-07 Ecole Polytechnique Federale De Lausanne (Epfl) Micelles for delivery of nitric oxide
WO2010005570A2 (en) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
US8961991B2 (en) 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
CN101750244B (zh) 2008-10-13 2014-03-12 艾博生物医药(杭州)有限公司 一种分离血液样本中红细胞的方法以及运用
WO2010045518A1 (en) 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
US8268977B2 (en) 2008-11-20 2012-09-18 The Board Of Trustees Of The Leland Stanford Junior University Strongly quenching oligomeric excimer/quencher pairs for detection schemes
CA3042826A1 (en) 2008-11-30 2010-06-03 Immusant, Inc. Compositions and methods for treatment of celiac disease
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
CA2750098A1 (en) 2009-01-20 2010-07-29 Myelin Repair Foundation, Inc. Compositions and methods for induction of antigen-specific tolerance
CA2754764A1 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
CA3032548C (en) 2009-03-10 2023-05-09 Baylor Research Institute Anti-cd40 antibodies and uses thereof
US9371386B2 (en) 2009-03-16 2016-06-21 Daniel A. Vallera Methods and compositions for bi-specific targeting of CD19/CD22
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
KR101770844B1 (ko) 2009-07-31 2017-08-23 아센디스 파마 에이에스 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
JP2013503204A (ja) 2009-08-31 2013-01-31 アンプリミューン， インコーポレイテッド Ｂ７−ｈ４融合タンパク質およびその使用方法
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
US20110091493A1 (en) 2009-10-16 2011-04-21 Northwestern University Vaccine compositions and uses thereof
HUE029150T2 (hu) * 2009-10-27 2017-02-28 Erytech Pharma Készítmény specifikus immuntolerancia indukálására
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
EP2523686A2 (en) * 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
WO2011092715A2 (en) 2010-01-27 2011-08-04 Tata Memorial Centre Method for in-vivo binding of chromatin fragments
EP2547328B1 (en) 2010-02-11 2017-06-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Ccr7 ligand delivery and co-delivery in immunotherapy
US9289510B2 (en) * 2010-03-08 2016-03-22 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
IT1399590B1 (it) 2010-04-26 2013-04-26 Erydel Spa Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
CA2797963A1 (en) 2010-04-30 2011-11-03 Augmenta Biologicals, Llc Delivery proteins
WO2011154887A1 (fr) * 2010-06-07 2011-12-15 Assistance Publique - Hopitaux De Paris Méllitine pour son utilisation dans le traitement de la maladie de parkinson
US9326939B2 (en) 2010-07-31 2016-05-03 The Scripps Research Institute Liposome targeting compounds and related uses
US9522183B2 (en) 2010-07-31 2016-12-20 The Scripps Research Institute Compositions and methods for inducing immune tolerance
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9175280B2 (en) 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
US20120121592A1 (en) 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2012112690A2 (en) 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
EP2717919B1 (en) * 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US10227290B2 (en) 2012-02-07 2019-03-12 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
CN110075283A (zh) * 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
US9751945B2 (en) 2012-04-13 2017-09-05 Whitehead Institute For Biomedical Research Sortase-modified VHH domains and uses thereof
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
US9688991B2 (en) 2012-07-13 2017-06-27 Albert Einstein College Of Medicine, Inc. Aptamer-targetted antigen delivery
JP2015525792A (ja) * 2012-08-09 2015-09-07 ロシュ グリクアート アクチェンゲゼルシャフト Ａｓｇｐｒ抗体およびその使用
WO2014052545A2 (en) 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
EP2964677A1 (en) 2013-03-04 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and immunoconjugates and uses thereof
CN105307725B (zh) 2013-04-11 2020-06-16 布里格姆及妇女医院股份有限公司 治疗自身免疫疾病的方法和组合物
US20160060324A1 (en) 2013-04-22 2016-03-03 James C. Paulson Methods and Compositions for Treating Bleeding Disorders
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10946079B2 (en) * 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) * 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
PL3125927T3 (pl) 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Sposoby i kompozycje do immunomodulacji
RU2711485C2 (ru) 2014-04-11 2020-01-17 МЕДИММЬЮН, ЭлЭлСи Конъюгированные соединения, содержащие сконструированные с цистеином антитела
WO2015171863A1 (en) 2014-05-08 2015-11-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. USING B-CELL-TARGETING ANTIGEN IgG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES
CA2949081C (en) 2014-05-16 2023-03-07 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
EP3188758B1 (en) 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
US20160060358A1 (en) 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016161372A1 (en) 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2016183361A1 (en) 2015-05-13 2016-11-17 Advaxis, Inc. Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof
EP3313874B1 (en) 2015-06-26 2021-03-10 University of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
WO2017015141A1 (en) 2015-07-17 2017-01-26 President And Fellows Of Harvard College Humanized anti-glycophorin a antibodies and uses thereof
EP3328377A4 (en) 2015-07-31 2019-03-13 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
WO2017025889A1 (en) 2015-08-13 2017-02-16 Pfizer Inc. Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist
US10864170B2 (en) 2015-09-04 2020-12-15 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
US10294294B2 (en) 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
CN108430497B (zh) 2015-09-19 2024-05-07 洛桑聚合联合学院 糖靶向治疗剂
CN108770357B (zh) 2015-09-29 2022-10-28 芝加哥大学 聚合物结合疫苗
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
EP3319622B1 (en) 2015-12-22 2020-02-12 CureVac AG Method for producing rna molecule compositions
WO2017112899A1 (en) 2015-12-23 2017-06-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
JP2019504895A (ja) 2016-02-09 2019-02-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
US20190046620A1 (en) 2016-02-12 2019-02-14 Bloodworks Therapeutic induction of tolerance using recombinant cell surface antigens
US20170252417A1 (en) 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
CN109475577A (zh) 2016-05-03 2019-03-15 Sqz生物技术公司 细胞内递送生物分子以诱导耐受性
CA3023092A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
US20170326213A1 (en) 2016-05-16 2017-11-16 Augusta University Research Institute, Inc. Protein-Coupled Red Blood Cell Compositions and Methods of Their Use
JP6687498B2 (ja) 2016-10-25 2020-04-22 住友ナコ フォ−クリフト株式会社 カメラ用装着ブラケット
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
EP3774890A4 (en) 2018-03-26 2022-05-04 The University of Chicago METHODS AND COMPOSITIONS FOR THE TARGETING OF C-TYPE LECTIN FROM SINUSOIDAL ENDOTHELIAL CELLS OF THE LIVER AND LYMPH NODES (LSECTIN)
JP2021522812A (ja) 2018-05-07 2021-09-02 アノキオン・ソシエテ・アノニムＡｎｏｋｉｏｎ Ｓａ グリコフォリンａ抗原結合タンパク質
EP3790577A4 (en) * 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
CN114728056A (zh) * 2019-09-20 2022-07-08 阿诺基昂股份公司 用于诱导抗原特异性免疫耐受的化合物

Also Published As

Publication number Publication date
KR20240154672A (ko) 2024-10-25
AU2021201504B2 (en) 2024-08-29
AU2015233084A1 (en) 2016-09-08
US20200121762A1 (en) 2020-04-23
NZ740388A (en) 2024-04-26
WO2015140648A2 (en) 2015-09-24
IL247283A0 (en) 2016-09-29
JP7562279B2 (ja) 2024-10-07
EA201691686A1 (ru) 2017-03-31
LT3107563T (lt) 2021-07-12
AU2015233084B2 (en) 2020-12-17
KR20230003288A (ko) 2023-01-05
JP2024037920A (ja) 2024-03-19
SG10202010936RA (en) 2020-12-30
IL283100A (en) 2021-06-30
IL247283B (en) 2021-05-31
JP2017507180A (ja) 2017-03-16
NZ723879A (en) 2018-03-23
KR102717969B1 (ko) 2024-10-15
US20260007723A1 (en) 2026-01-08
ES2874884T3 (es) 2021-11-05
EP3107563B1 (en) 2021-04-07
JP2022070910A (ja) 2022-05-13
JP2020121981A (ja) 2020-08-13
EP3107563A2 (en) 2016-12-28
JP6744227B2 (ja) 2020-08-19
HK1232151A1 (zh) 2018-01-05
IL283100B2 (en) 2023-06-01
SG11201606761RA (en) 2016-09-29
NZ761836A (en) 2024-04-26
AU2021201504A1 (en) 2021-03-25
US20160015821A1 (en) 2016-01-21
CA2946064A1 (en) 2015-09-24
US11666638B2 (en) 2023-06-06
WO2015140648A3 (en) 2016-01-14
MX2021012636A (es) 2022-01-04
AU2024266808A1 (en) 2024-12-19
DK3107563T3 (da) 2021-05-25
US10821157B2 (en) 2020-11-03
BR112016019274A2 (pt) 2017-10-10
US20230108299A1 (en) 2023-04-06
MX388754B (es) 2025-03-20
KR20160135214A (ko) 2016-11-25
EP3909603A1 (en) 2021-11-17
CN106456743A (zh) 2017-02-22
CA2946064C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
MX2016010835A (es) Terapeuticos dirigidos a la glucosa.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CA166702S (en) Blood pressure monitor
CA166574S (en) Blood pressure monitor
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
AU364639S (en) Massage chair
BR112017002074A2 (pt) vestuário e método de compressão médica terapêutica
CA159367S (en) Fryer
CA167903S (en) Basket for fryer
MX2023006415A (es) Anticuerpos, usos y metodos.
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
MX2021008663A (es) Anticuerpos mejorados contra il-6.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12017501979A1 (en) Pharmaceutical compound
AU355238S (en) Dental appliance
CA166570S (en) Wearable health monitor
CA166572S (en) Display for wearable health monitor
CA166573S (en) Display with charger for wearable health monitor
CA167033S (en) Fryer
CA167034S (en) Fryer
CA157729S (en) Speaker
CA164923S (en) Dental capsule